Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

Krabbe Disease Clinical Trial

Official title:

A Long-term Follow-up Study to Evaluate Safety and Efficacy of Krabbe Patients From Gene Therapy Clinical Trials Involving the Administration of FBX-101 (AAVrh.10-hGALC)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06308718
• Other study ID #: FBX-101-LTFU
• Status: Not yet recruiting
• Start date: June 2024
• Est. completion date: December 2029

Study information

• Verified date: May 2024
• Source: Forge Biologics, Inc
• Contact: Kelly Bossola
• Phone: +1.380.239.2052
• Email: advocacy[@]forgebiologics.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is an observational study that will enroll any patients with Krabbe disease that have participated in prior interventional clinical trials involving the administration of FBX-101.

Description:

FBX-101-LTFU is a multicenter, non-interventional, Long-Term Follow-Up (LTFU) study of participants from prior interventional trials involving the administration of FBX-101. Eligible participants will undergo clinical evaluations at prespecified intervals for at least 3 years from the last visit in the prior clinical trial (up to 5 years post-FBX-101 treatment). Overall safety and additional signs of efficacy will be collected with a series of laboratory tests, diagnostic tests, and performance surveys. Additionally, children participating in interventional trials that are terminated early will be transferred to this LTFU study and will complete any pending visits from the interventional trial before starting the clinical evaluations included in this protocol.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 25
• Est. completion date: December 2029
• Est. primary completion date: December 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Participants that have completed a prior clinical trial involving the administration of FBX-101.

• Parent(s)/legal guardian(s) of participant willing and able to complete the informed consent process and comply with study procedures and visit schedule.

Exclusion Criteria:

•Planned or current participation in any other interventional clinical study that may confound the safety or efficacy evaluation of FBX-101 during this study.

Related Conditions & MeSH terms

• Krabbe Disease
• Leukodystrophy, Globoid Cell

Intervention

Biological:
• FBX-101
A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (hGALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.

Locations

Country	Name	City	State
United States	University of Michigan Hospitals - Michigan Medicine	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Forge Biologics, Inc

Country where clinical trial is conducted

United States, 

References & Publications (9)

Bascou N, DeRenzo A, Poe MD, Escolar ML. A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life. Orphanet J Rare Dis. 2018 Aug 9;13(1):126. doi: 10.1186/s13023-018-0872-9. — View Citation

Beltran-Quintero ML, Bascou NA, Poe MD, Wenger DA, Saavedra-Matiz CA, Nichols MJ, Escolar ML. Early progression of Krabbe disease in patients with symptom onset between 0 and 5 months. Orphanet J Rare Dis. 2019 Feb 18;14(1):46. doi: 10.1186/s13023-019-1018-4. — View Citation

Bradbury AM, Bagel J, Swain G, Miyadera K, Pesayco JP, Assenmacher CA, Brisson B, Hendricks I, Wang XH, Herbst Z, Pyne N, Odonnell P, Shelton GD, Gelb M, Hackett N, Szabolcs P, Vite CH, Escolar M. Combination HSCT and intravenous AAV-mediated gene therapy in a canine model proves pivotal for translation of Krabbe disease therapy. Mol Ther. 2024 Jan 3;32(1):44-58. doi: 10.1016/j.ymthe.2023.11.014. Epub 2023 Nov 11. — View Citation

Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, Wenger DA, Pietryga D, Wall D, Champagne M, Morse R, Krivit W, Kurtzberg J. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2005 May 19;352(20):2069-81. doi: 10.1056/NEJMoa042604. — View Citation

Gupta A, Poe MD, Styner MA, Panigrahy A, Escolar ML. Regional differences in fiber tractography predict neurodevelopmental outcomes in neonates with infantile Krabbe disease. Neuroimage Clin. 2014 Sep 26;7:792-8. doi: 10.1016/j.nicl.2014.09.014. eCollection 2015. — View Citation

Siddiqi ZA, Sanders DB, Massey JM. Peripheral neuropathy in Krabbe disease: effect of hematopoietic stem cell transplantation. Neurology. 2006 Jul 25;67(2):268-72. doi: 10.1212/01.wnl.0000230156.01228.33. — View Citation

Vander Lugt MT, Chen X, Escolar ML, Carella BA, Barnum JL, Windreich RM, Hill MJ, Poe M, Marsh RA, Stanczak H, Stenger EO, Szabolcs P. Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders. Blood Adv. 2020 Jul 14;4(13):3041-3052. doi: 10.1182/bloodadvances.2020001940. Erratum In: Blood Adv. 2020 Aug 11;4(15):3508. — View Citation

Wright MD, Poe MD, DeRenzo A, Haldal S, Escolar ML. Developmental outcomes of cord blood transplantation for Krabbe disease: A 15-year study. Neurology. 2017 Sep 26;89(13):1365-1372. doi: 10.1212/WNL.0000000000004418. Epub 2017 Aug 30. — View Citation

Yoon IC, Bascou NA, Poe MD, Szabolcs P, Escolar ML. Long-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease. Blood. 2021 Apr 1;137(13):1719-1730. doi: 10.1182/blood.2020005477. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Long Term safety as assessed by incidence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) that are attributed to FBX-101		36 months
Secondary	Efficacy as assessed by change of gross motor function measured longitudinally by Peabody Developmental Motor Scale (PDMS-2)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of gross motor function measured longitudinally by Bruininks-Oseretsky Test of Motor Proficiency (BOT-2)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of gross motor function measured longitudinally by Gross Motor Function Measure 88 (GMFM-88)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of fine motor function measured longitudinally by Mullen Scales of Early Learning (MSEL)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of fine motor function measured longitudinally by Beery VMI Sixth Edition (VMI)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of fine motor function measured longitudinally by Bayley Scales of Infant Development (Bayley-III)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of fine motor function measured longitudinally by Vineland Adaptive Behavior Scale (Vineland 3)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of cognitive function measured longitudinally by Mullen Scales of Early Learning (MSEL)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of cognitive function measured longitudinally by the Differential Ability Scale II (DAS-II)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of cognitive function measured longitudinally by Bayley Scales of Infant Development (Bayley-III)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of adaptive behaviour function measured longitudinally by Vineland Adaptive Behavior Scale (Vineland 3).	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of language function measured longitudinally by Mullen Scales of Early Learning (MSEL).	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of language function measured longitudinally by Clinical Evaluation of Language Fundamentals Fifth Edition (CELF-5)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of language function measured longitudinally by Bayley Scales of Infant Development (Bayley-III)	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of language function measured longitudinally by Vineland Adaptive Behavior Scale (Vineland 3).	The site is providing raw data and sponsor is calculating derived scores according to specific manual. Higher values will mean better outcome.	36 months
Secondary	Efficacy as assessed by change of quality of life measured longitudinally by the Pediatric Quality of Life (PedsQL) Generic Core Scales with Family Impact Module and Multidimensional Fatigue Scale		36 months
Secondary	Efficacy as assessed by change of developmental milestones such as language and motor skills as measured longitudinally by an specific Developmental Milestones questionnaire		36 months
Secondary	Efficacy as assessed by change of hearing function measured longitudinally by Auditory Brainstem Responses (ABRs)	Absolute values for Waves I, III and V in milliseconds will be recorded along interpretation and waveform morphology; and also Auditory Brainstem Responses (corrected).	36 months
Secondary	Efficacy as assessed by change of hearing function measured longitudinally by Behavior Audiometry (BAUD)		36 months
Secondary	Efficacy as assessed by change of peripheral nerve conduction velocity measured longitudinally by Nerve Conduction Velocity (NCV) assessments		36 months
Secondary	Efficacy as assessed by change of Fractional Anisotropy (FA) as measured longitudinally by brain Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)		36 months
Secondary	Efficacy as assessed by change of visual function as measured longitudinally by visual evoked potentials (VEP)		36 months
Secondary	Efficacy as assessed by change of visual function as measured longitudinally by visual acuity		36 months
Secondary	Efficacy as assessed by change of whole blood donor chimerism		36 months
Secondary	Efficacy as assessed by change of psychosine in whole blood and plasma		36 months
Secondary	Efficacy as assessed by change of Galactosylceramidase (GALC) levels in plasma and Cerebrospinal Fluid (CSF)		36 months